View clinical trials related to Non-Hodgkins Lymphoma.
Filter by:Participants who qualify will receive lenalidomide daily on days 1-21 of every 28 day cycle. Treatment will continue for up to 52 weeks or until disease progression; participants who achieve a complete response (CR) will receive an additional 2 cycles of treatment prior to discontinuation. Participants will be followed for progression free survival following discontinuation from the treatment phase
To determine the activity of lenalidomide in relapsed or refractory aggressive NHL.